Pal Sukumar, Favaroni Alison, Tifrea Delia F, Hanisch Philipp T, Luczak Sören E T, Hegemann Johannes H, de la Maza Luis M
Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA.
Institut für Funktionelle Genomforschung der Mikroorganismen, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Vaccine. 2017 May 2;35(19):2543-2549. doi: 10.1016/j.vaccine.2017.03.070. Epub 2017 Apr 3.
To test vaccines, formulated with novel antigens, to protect mice against Chlamydia infections.
To determine the ability of polymorphic membrane proteins (Pmps) to induce cross-species protective immune responses, recombinant fragments from all nine C. trachomatis serovar E Pmps were used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 as adjuvants. C. muridarum recombinant MOMP and PBS, formulated with the same adjuvants, were used as positive and negative controls, respectively. Mice were challenged intranasally with 10 inclusion-forming units (IFU) of C. muridarum. Animals were weighed daily and at 10days post-challenge, they were euthanized, their lungs harvested, weighed and the number of chlamydial IFU counted.
Following vaccination the nine Pmps elicited immune responses. Based on body weight changes, or number of IFU recovered from lungs, mice vaccinated with Pmp C, G or H were the best protected. For example, over the 10-day period, the negative control group vaccinated with PBS lost significantly more body weight than mice immunized with PmpC or G (P<0.05). C. muridarum MOMP vaccinated mice were better protected against body weight losses than any group immunized with Pmps. Also, the median number of IFU recovered from the lungs of mice vaccinated with PmpC (72×10) or PmpH (61×10) was significantly less than from mice immunized with PBS (620×10; P<0.05). As determined by the number of IFU, all Pmps elicited less protection than C. muridarum MOMP (0.078×10 IFU; P<0.05).
This is the first time PmpC has been shown to elicit cross-species protection against a respiratory challenge. Additional work with Pmps C, G and H is recommended to determine their ability to protect animal models against genital and ocular challenges.
测试用新型抗原配制的疫苗，以保护小鼠免受衣原体感染。
为了确定多态性膜蛋白（Pmps）诱导跨物种保护性免疫反应的能力，来自沙眼衣原体血清型E所有9种Pmps的重组片段，利用CpG-1826和Montanide ISA 720作为佐剂，用于给BALB/c小鼠接种疫苗。用相同佐剂配制的鼠衣原体重组主要外膜蛋白（MOMP）和磷酸盐缓冲盐水（PBS）分别用作阳性和阴性对照。小鼠经鼻内接种10个鼠衣原体包涵体形成单位（IFU）。每天称动物体重，在攻毒后10天，对它们实施安乐死，取出肺脏，称重并计算衣原体IFU的数量。
接种疫苗后，9种Pmps引发了免疫反应。根据体重变化或从肺中回收的IFU数量，接种Pmp C、G或H的小鼠受到的保护最佳。例如，在10天期间，接种PBS的阴性对照组体重损失明显多于接种PmpC或G的小鼠（P<0.05）。接种鼠衣原体MOMP的小鼠比任何接种Pmps的组在防止体重减轻方面受到更好的保护。此外，从接种PmpC（72×10）或PmpH（61×10）的小鼠肺中回收的IFU中位数明显少于接种PBS的小鼠（620×10；P<0.05）。根据IFU数量确定，所有Pmps引发的保护作用均小于鼠衣原体MOMP（0.078×10 IFU；P<0.05）。
这是首次证明PmpC能引发针对呼吸道攻毒的跨物种保护作用。建议对Pmps C、G和H开展更多研究，以确定它们保护动物模型免受生殖道和眼部攻毒的能力。
